Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
Go back to Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026| (NASDAQ: XENE) | Delayed: 35.64 -0.86 (2.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.50 | 52 Week High | $9.75 | |||
| Open | $36.62 | 52 Week Low | $5.65 | |||
| Day High | $36.62 | P/E | N/A | |||
| Day Low | $35.41 | EPS | $0.00 | |||
| Volume | 155,478 | |||||
| (NASDAQ: XENE) | Delayed: 35.64 -0.86 (2.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.50 | 52 Week High | $9.75 | |||
| Open | $36.62 | 52 Week Low | $5.65 | |||
| Day High | $36.62 | P/E | N/A | |||
| Day Low | $35.41 | EPS | $0.00 | |||
| Volume | 155,478 | |||||



